Skip to main content
. 2019 Apr 17;40(12):1480–1491. doi: 10.1093/carcin/bgz069

Figure 1.

Figure 1.

MDC-1112 inhibits GBM cell growth. (A) Chemical structure of MDC-1112 (Phospho-valproic acid). (B) IC50 values for glioblastoma cells treated with MDC-1112 or VPA for 24 h. These values are representative of three experiments, each performed in triplicates; results were within 10%. The table shows the 13.4- to 25.4-fold enhancements in potency of MDC-1112 over VPA in four human GBM cell lines. (C) MDC-1112 reduces human U87 cell growth in a concentration- and time-dependent manner. Results are expressed as % control. (D) MDC-1112 inhibits GBM cell colony formation in a concentration-dependent manner in U87 and LN-18 cells. (*P < 0.05, versus control). (E) Differential cytotoxic effect of MDC-1112 in GBM cells compared with the NHA. MDC-1112 inhibits human GBM cancer cell growth in a concentration-dependent manner. Cell growth was determined in U118, LN-229 and LN-18 GBM cells and in NHA after treatment with escalating concentrations of MDC-1112 for 48 h. Results are expressed as % control. *Significantly different compared with all other cell lines (P < 0.05, one-way analysis of variance test).